NASDAQ · Biotechnology

ANTX (ANTX) Stock

$4.93 +0.20% NASDAQ: ANTX Healthcare

Valuation

MetricValue
Price$4.93
Market Cap$177.56M
P/E Ratio-4.76
P/B Ratio2.18
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$6.91
52-Week Low$1.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.56%
ROA-27.48%
ROCE-71.70%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-22.0M$-42.0M$-70.0M$-55.0M$-38.0M
Net Profit$-22.0M$-41.0M$-65.0M$-51.0M$-35.0M
EPS$-1.50$-2.79$-2.74$-1.72$-1.16
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$65.0M$103.0M$139.0M$92.0M$62.0M
Total Liabilities$3.0M$7.0M$14.0M$10.0M$9.0M
Cash$12.0M$27.0M$16.0M$21.0M$20.0M
Borrowings$0$0$0$0$0

Latest News

AN2 Therapeutics Says Chagas Disease Drug Shows Positive Preclinical, Early Human Data MT Newswires · Jun 4, 2026 AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Business Wire · Jun 4, 2026 Correction: Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1 MT Newswires · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-20.0M$-33.0M$-53.0M$-49.0M$-30.0M
Investing Cash Flow$-50.0M$-22.0M$-43.0M$55.0M$28.0M
Financing Cash Flow$-1.0M$0$0$0$0
Net Cash Flow$8.0M$15.0M$-12.0M$6.0M$-1.0M
Free Cash Flow$-20.0M$-33.0M$-53.0M$-49.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-15.13
EV / EBITDA—
FCF Yield-23.06%
Quick Ratio15.73
Interest Coverage—
Return 1Y344.86%
Return 3Y-39.82%
Return 5Y—

Ownership

Insiders Held18.99%
Institutions Held70.60%
Institutions Float Held87.14%
Institutional HolderSharesReport Date
Vivo Capital, LLC3,153,6402026-03-31
Commodore Capital Lp2,333,7132026-03-31
Millennium Management Llc2,222,5022026-03-31
Spruce Street Capital LP1,661,0732026-03-31
Almitas Capital LLC1,479,1292026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLD $2.48 -3.50% -0.56 $55.74M 0.00%
IBIO $1.45 +1.40% -0.91 $22.89M 0.00%
INTS $4.57 +2.70% -0.60 $12.35M 0.00%
ITRMIterum Therapeutics plc $0.03 -10.98% -0.06 $1.60M 0.00%
NXTC $5.00 +17.81% -0.26 $18.04M 0.00%

About ANTX

ANTX is led by CEO Eric E. Easom, employs 22 people, headquartered in US, publicly traded since 2022.

ANTX stock trades at $4.93 with a market capitalization of $177.56M. The stock is valued at a price-to-earnings (P/E) ratio of -4.76, price-to-book of 2.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.00 and $6.91, and currently trades 28.7% below its 52-week high.

On profitability, ANTX generates a return on equity (ROE) of -44.56%, return on capital employed of -71.70%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides